Clear Street initiated coverage of Equillium (NASDAQ: EQ) with a “buy” rating and price target of $9.00. The stock closed at $2.47 on July 20. Equillium is a clinical-stage biotechnology company developing therapies...
Cantor Fitzgerald launched coverage of Equillium (NASADQ:EQ) with an “overweight” rating and $14 price target. The stock closed at $5.40 on Sept. 14. Equillium is developing itolizumab, its novel CD6 targeted monoclonal...